RDY
Trust-weighted public proof page for RDY. See which authors support it, which ticker theses it belongs to, and how thesis calls have performed.
Recent proof-backed thesis calls
Public preview of asset-level thesis calls linked to source content, observed prices, and outcomes.
Bloomberg segment highlights a proposed 100% US tariff on generic drugs with a two-year delay (implemented in/around 2028), alongside broader tariff threats discussed at ASEAN meetings, geopolitical risk (Iran/Red Sea), and near-term focus on mega-cap tech earnings (Alphabet, Tesla, Intel) plus yen/BOJ outlook and India protectionism creating local winners.
Trump said generic drug manufacturers will have two years to move production to the US or face a 100% import tariff starting in 2028. If implemented, this would materially raise the cost of imported generics and could incentivize US onshoring/US-based capacity additions, while pressuring foreign-heavy generic suppliers and downstream pharmacy/wholesaler margins (unless pricing is passed through). Key uncertainty is political/legal feasibility and whether it becomes actual policy vs campaign post
Current stance
- risk via Trade-policy risk premium rises for import-exposed generic supply chains; relative benefit to firms with more flexible/US-linked manufacturing. from https://www.youtube.com/channel/UCIALMKvObZNtJ6AmdCLP7Lg (confidence 0.48)
- risk via US protectionism headline: optional uplift for US/ diversified generic manufacturers; risk for import-heavy supply chain and drug-cost-sensitive intermediaries from https://www.youtube.com/channel/UCIALMKvObZNtJ6AmdCLP7Lg (confidence 0.43)
Top authors on this asset
Active and historical ticker theses
Trade-policy risk premium rises for import-exposed generic supply chains; relative benefit to firms with more flexible/US-linked manufacturing.
US protectionism headline: optional uplift for US/ diversified generic manufacturers; risk for import-heavy supply chain and drug-cost-sensitive intermediaries
Unlock full asset monitoring
Create an account to access full asset history, alerts, Telegram workflows, and trust-weighted live rankings across authors, ticker theses, and market events.